Clinical UM Guideline

This document addresses the use of the partial thromboplastin time (PTT) test, also called activated PTT (APTT) an in vitro laboratory assay used to assess the intrinsic coagulation pathway and monitor anticoagulation therapy. PTT testing is commonly used to monitor the effects of unfractionated heparin therapy and to evaluate individuals with suspected bleeding or thrombotic disorders.

Note: For PTT testing performed in low-risk invasive procedures, see the following:

• CG-MED-61 Preoperative Testing for Low Risk Invasive Procedures and Surgeries

Note: See the following for other preoperative or screening tests:

• CG-MED-62 Resting Electrocardiogram Screening in Adults

Note: Please see the following for information on home prothrombin time (PT) testing:

• CG-DME-30 Prothrombin Time Self-Monitoring Devices

Medically Necessary:

PTT or APTT testing is considered medically necessary for any of the following indications:

1. Monitor heparin therapy
   1. Monitor unfractionated heparin therapy (effect and dosing); or
   2. Transition from heparin to warfarin therapy;
      or
2. Diagnostic evaluation of hemorrhage or thrombosis
   1. Evaluation of abnormal bleeding suggestive of coagulopathy (for example, hemorrhage, petechiae, hematoma); or
   2. Evaluation of possible thrombosis (for example, swollen extremity with or without trauma);
      or
3. Evaluation of individuals with conditions associated with coagulopathy, including but not limited to:
   1. Congenital/acquired bleeding disorder; or
   2. Liver disease or failure (including Wilson’s disease); or
   3. Disseminated intravascular coagulation (DIC); or
   4. Lupus erythematosus or other inhibitor states (for example., factor VIII inhibitor, lupus anticoagulant); or
   5. Sepsis or infectious processes associated with abnormal coagulation; or
   6. Renal failure or nephrotic syndrome; or
   7. Hypercoagulable states, arterial or venous thrombosis;
      or
4. Evaluation prior to an invasive procedure when any of the following criteria (1 or 2) are met:
   1. The same test has not been performed in the previous 30 days; or
   2. Repeat testing within the 30 day window in an individual who meets any of the following conditions:
      1. Personal or family history of bleeding or thrombosis; or
      2. Current or recent heparin therapy; or
      3. Documented or suspected coagulation abnormalities; or
      4. Age 65 or older.

Repeat PTT or APTT is considered medically necessary when used to:

1. Monitor response to therapy; or
2. Assess a change in clinical status, such as new or unexplained bleeding, thrombosis, or suspicion of disease progression or intercurrent illness affecting coagulation.

Not Medically Necessary:

PTT or APTT testing is considered not medically necessary when the criteria above are not met.

The following codes for treatments and procedures applicable to this guideline are included below for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

When services are Medically Necessary:

When services may be Medically Necessary when criteria are met:
For the procedure code listed above for all other diagnoses not listed.

When services are Not Medically Necessary:
For the procedure code listed above when criteria are not met.

Summary

PTT and APTT are fundamental coagulation tests that provide essential diagnostic and therapeutic guidance in anticoagulation management, pre-procedure risk stratification, and evaluation of bleeding and thrombotic conditions. While it has broad utility, its clinical utility may be limited to clinical scenarios supported by medical necessity, as outlined above.

These tests are commonly used to monitor individuals receiving unfractionated heparin therapy, evaluating individuals with abnormal bleeding or thrombosis, and diagnosing or managing individuals with coagulopathy associated with liver disease, renal failure, sepsis, autoimmune disorders, or hypercoagulable states. PTT/APTT may also be appropriate before invasive procedures in high-risk individuals, such as those with a personal or family history of bleeding, on heparin therapy, or over age 65. Repeat testing is warranted to monitor therapy response or investigate new symptoms.

Clinically, PTT and APTT assess the intrinsic and common coagulation pathways. They are essential in identifying bleeding disorders such as hemophilia A and B, acquired hemophilia A, von Willebrand disease, and lupus anticoagulant-associated conditions. PTT is often prolonged in these disorders, but not always indicative of bleeding risk, as in antiphospholipid syndrome. In liver diseases like Wilson’s disease, and in disseminated intravascular coagulation (DIC), abnormal PTT and APTT reflects impaired coagulation due to dysfunction or systemic activation of clotting pathways. These assays are part of the initial work-up for bleeding or thrombotic events and can guide diagnosis, treatment, and prognosis.

Pre-procedurally, PTT and APTT is used to assess thrombotic risk, particularly in conditions like lumbar degenerative disease where surgery amplifies prothrombotic pathways. Guidelines from several nationally respected organizations, including the American College of Cardiology (ACC), the American Association for the Study of Liver Diseases (AASLD), the American Society of Anesthesiologists (ASA), and the National Comprehensive Cancer Network^® (NCCN), recommend selective rather than routine use of these tests, with particular emphasis on individuals at elevated risk (e.g., elderly, cancer patients, those with hematologic disorders). Although newer assays are preferred for direct oral anticoagulants, PT and APTT remain widely used due to accessibility and broad diagnostic utility.

Discussion

PTT and APTT measure the function of the intrinsic and common coagulation pathways by timing how long it takes plasma to clot. While PTT measures clotting time of plasma alone, APTT is performed by adding an activator, such as kaolin and cephalin. APTT is considered to be more specific for certain conditions and have a narrower range. PTT evaluates all clotting factors as well as fibrinogen, except factor VII and factor XIII. A prolonged PTT suggests abnormalities in the intrinsic pathway, such as deficiencies of factors VIII or IX (hemophilia A or B), von Willebrand disease (via reduced FVIII protection), or acquired conditions like vitamin K deficiency, liver disease, or disseminated intravascular coagulation. A prolonged PTT can also result from the presence of an inhibitor. A shortened PTT is often associated with elevated factor VIII levels and could signal an increased risk of thrombosis (Zaidi, 2024). PTT remains normal in isolated factor VII deficiency and in factor XIII deficiency, as factor XIII acts after clot formation during fibrin stabilization.

Acquired hemophilia A is a rare bleeding disorder caused by autoantibodies that inhibit coagulation factor VIII, leading to impaired clot formation and a high risk of spontaneous or severe bleeding. Unlike congenital hemophilia, it typically arises in adults without a prior bleeding history and is often associated with autoimmune disease, malignancy, postpartum state, or can be idiopathic. Diagnosis is suggested by an isolated prolonged APTT that fails to correct on mixing studies, and confirmation requires demonstration of low factor VIII activity with an inhibitor.

In lupus, particularly antiphospholipid syndrome (APS), the APTT is often prolonged due to lupus anticoagulant, autoantibodies directed against phospholipid-binding proteins that interfere with phospholipid-dependent clotting assays. Lupus anticoagulant is not associated with bleeding; but does represent a prothrombotic risk. In lupus/APS, PTT serves primarily as a screening and diagnostic clue for lupus anticoagulant, rather than a measure of bleeding tendency (Jacobs, 2022).

Clinically, PTT is widely used in three major settings: (1) monitoring unfractionated heparin therapy, where therapeutic targets are set at 60-100 seconds depending on dosing intensity, (2) screening individuals for inherited or acquired bleeding disorders, and (3) evaluating unexplained thrombotic or hemorrhagic conditions as part of a coagulation panel. It can also be prolonged artifactually in antiphospholipid antibody syndrome (due to the lupus anticoagulant), which paradoxically predisposes to thrombosis despite in vitro prolongation. While anti-Xa assays are increasingly used for precise heparin monitoring, PTT remains a cornerstone due to its accessibility, established clinical utility, and broad diagnostic role. Thus, PTT testing serves as a critical tool for both anticoagulant management and for identifying defects across much of the coagulation cascade.

Heparin therapy

Heparin therapy is delivered as either low-molecular-weight heparin (LMWH) or unfractionated heparin (UFH). LMWHs provide a predictable anticoagulation with fixed, weight-based subcutaneous dosing. LMWHs are widely used in both prophylaxis and treatment of thromboembolic disease. LMWHs and rapidly acting oral anticoagulants have largely replaced unfractionated heparin therapy as generally they do not require laboratory monitoring. In special circumstances in which LMWH activity requires monitoring, it is assessed using anti-factor Xa levels. In contrast, UFH therapy is used in individuals at high risk of both bleeding and thrombosis and when rapid titration, close monitoring, or full reversibility with protamine sulfate is required (for example, in acute care, perioperative settings, or advanced renal impairment). Monitoring UFH therapy is done using PTT testing.

PTT and Coagulation Disorders

In individuals with new-onset severe bleeding, initial screening should include APTT and PT. An isolated prolonged APTT should prompt a 1:1 mixing study with normal plasma. In acquired hemophilia A (AHA), the APTT remains prolonged after mixing, indicating an inhibitor, most often against FVIII. FVIII activity should therefore be measured first; reduced FVIII strongly suggests AHA, and antibody titers should be confirmed using the Nijmegen-modified Bethesda assay. FVIII inhibitors in AHA often display type 2 kinetics, complicating titer interpretation (Bannoud, 2024).

By contrast, in acquired von Willebrand syndrome (aVWS), diagnosis relies on patient history, absence of family history, and abnormal VWF parameters. Screening shows prolonged closure time on platelet function analyzer and prolonged APTT. However, unlike AHA, the mixing study corrects the APTT, since no FVIII inhibitor is present (Bannoud, 2024).

A combination of coagulation laboratory testing, including APTT, PT, bleeding time and platelet count may be used during the initial diagnostic phase of a bleeding disorder. These findings allow for a provisional classification of the bleeding disorder, guiding subsequent analysis. The presence of a prolonged APTT may be indicative of hemophilia A or B or von Willebrand disease (Srivastava, 2013).

The 2020 ACC Expert Consensus Decision Pathway (Tomaselli, 2020) recommends that in patients presenting with clinically relevant bleeding while on oral anticoagulants, basic coagulation testing should always include PT and APTT, even though these tests have important limitations for direct oral anticoagulants (DOACs). For vitamin K antagonists, PT/INR is reliable for guiding management, but for DOACs, PT/APTT may only provide qualitative information and lack sensitivity or specificity depending on the agent and assay used. Specialized assays (e.g., dilute thrombin time for dabigatran, chromogenic anti-factor Xa assays for apixaban, edoxaban, rivaroxaban) are preferred where available, but they are not universally accessible. The consensus emphasizes that a normal PT/APTT does not reliably exclude clinically significant DOAC levels, while a prolonged result may suggest on- or above-therapy drug levels, though interpretation is reagent-dependent. Thus, PT and APTT are recommended as initial, widely available screening tools, with the understanding that their limitations require cautious interpretation, and that they should be supplemented with drug-specific assays when clinical decisions hinge on accurate anticoagulant quantitation.

DIC, typically an acute process, is a consumptive coagulopathy triggered by systemic activation of the coagulation cascade, often triggered by sepsis, trauma, or other critical illness. There is sudden, systemic activation of coagulation, leading to rapid consumption of clotting factors and platelets, which manifests as simultaneous microvascular thrombosis and bleeding. Individuals at highest risk include those with severe infections, trauma, or underlying thrombophilia, where pre-existing procoagulant states amplify the dysregulated response. There is a less common form of DIC, chronic or subacute. This form is more often associated with solid tumors or large aortic aneurysms, where coagulation is activated at a slower rate, and the body partially compensates. These individuals may present with more subtle laboratory abnormalities and a higher risk of thrombosis than bleeding. Clinical monitoring relies on serial laboratory tests including prolonged PT and APTT, thrombocytopenia, elevated fibrin degradation products (e.g., D-dimer), and reduced fibrinogen. These status of these clinical indicators reflect ongoing thrombin generation, factor consumption, and impaired fibrinolysis.

Liver Disorders

Liver disease profoundly alters coagulation because the liver produces nearly all clotting factors, anticoagulant proteins, and regulators of fibrinolysis. Damage to the liver reduces synthesis of procoagulant factors (II, V, VII, IX, X, XI) and anticoagulants (protein C, protein S, antithrombin), while portal hypertension causes thrombocytopenia and vitamin K deficiency further impairs factor production. This creates a “rebalanced but unstable” hemostatic state in which an affected individual face risks of both bleeding (from decreased clotting capacity and platelet dysfunction) and thrombosis (from loss of natural anticoagulants and enhanced endothelial activation). Individuals with liver cirrhosis and splenomegaly have a significant risk of coagulation dysfunction. In a retrospective study by Luv (2023), 80% of affected individuals had coagulation dysfunction.

A 2022 practice guidance by the AASLD outlines the diagnosis and management of Wilson Disease. In Wilson’s disease, an autosomal recessive disorder caused by ATP7B mutations, impaired biliary copper excretion results in progressive hepatic copper accumulation. The ensuing hepatocellular injury can lead to cirrhosis or acute liver failure and is frequently associated with clinically significant coagulopathy. Characteristic defects include reduced synthesis of clotting factors, a vitamin K-independent coagulopathy, and in fulminant presentations, profound coagulopathy that is typically unresponsive to vitamin K administration. Superimposed hemolysis and hypersplenism-related thrombocytopenia may further exacerbate bleeding risk, while disruption of the balance between procoagulant and anticoagulant pathways also predisposes patients to thrombotic events. The guidance recommends coagulation testing marker of hepatic synthetic function and prognosis in Wilson’s disease.

Preprocedural Evaluation

Virchow’s triad explains venous thrombosis as the interaction of stasis, endothelial injury, and hypercoagulability. Stasis from immobility or venous obstruction slows blood flow, endothelial injury from surgery, trauma, or catheters disrupts the vessel’s anticoagulant surface, and inherited or acquired prothrombotic states such as malignancy, pregnancy, or hormonal therapy increase clotting potential. In practice, most individuals exhibit overlapping risks across these mechanisms, which collectively drive the development of deep vein thrombosis (DVT). Hypercoagulability status is assessed by coagulation assays which would include PTT.

Individuals with lumbar degenerative disease (LDD) face a heightened risk of DVT because the condition and its surgical management activate all three elements of Virchow’s triad. Prolonged immobility and reduced ambulation lead to venous stasis, while muscle weakness and atrophy diminish the calf muscle pump needed for venous return. Surgical intervention and nerve root compression contribute to endothelial injury, further promoting thrombus formation. In addition, perioperative changes induce a hypercoagulable state, as reflected in abnormalities of coagulation markers such as D-dimer and APTT. Together, these factors create a pathophysiological environment highly conducive to thrombogenesis. Yang and associates (2025) evaluated individuals with lumbar degenerative disease prior to surgery in order to develop a risk prediction model for assessing for preoperative thrombi which could progress perioperative complications. The authors identified 5 independent predictors: age, walking impairment, diabetes mellitus, D-dimer, and APTT. Abnormal APTT was associated with nearly a fivefold increased risk of DVT, underscoring its value as a coagulation biomarker in preoperative risk assessment. When APTT was combined with D-dimer, the results showed markedly enhanced predictive accuracy.

Current professional guidelines, including the ASA Practice Advisory for Preanesthesia Evaluation (Apfelbaum, 2012), do not endorse routine preoperative PTT testing based solely on age. However, adults aged 65 years and older have a higher prevalence of coagulation abnormalities due to age-related physiologic and pathologic changes, which may result in or contribute to postoperative complications (Kruse-Jarres, 2015; Lee, 2021; Malpani, 2020; Mari, 2008). While chronological age alone is not an independent indication for preoperative coagulation testing, selective PTT testing may be appropriate in older adults with additional risk factors or suspicious findings.

Analyses of large surgical databases, including studies by Taylor (2021) and Benarroch-Gampel (2012), evaluated the utility of routine preoperative laboratory testing such as PTT performed within 30 days prior to elective procedures. Both studies defined the preoperative testing window as 30 days and found that while abnormal laboratory values were common, these abnormalities did not correlate with increased postoperative complications, morbidity, or mortality. The 30-day timeframe is therefore used as a standard reference period to capture relevant preoperative laboratory assessments while minimizing unnecessary repeat testing, as results within this interval are generally considered clinically valid and reflective of the individual’s current coagulation status unless new risk factors are present.

The NCCN Clinical Practice Guidelines (CPGs) for acute myeloid leukemia (AML) (V2.2026) note the following about both AML and acute promyelocytic leukemia (APL):

Coagulopathy is common at presentation in many leukemias; it is therefore standard clinical practice to screen for coagulopathy by evaluating prothrombin time (PT), partial thromboplastin time (PTT), and fibrinogen activity as part of the initial evaluation and before performing any invasive procedure.

In the NCCN CPG for cancer-associated venous thromboembolic disease (V2.2025), baseline PT and APTT are recommended in the initial evaluation of suspected VTE, including acute DVT and PE. Obtained alongside CBC, renal/hepatic function tests, and imaging, these assays help detect coagulopathies that may alter management; for instance, an abnormal PT or APTT (excluding lupus anticoagulant-related prolongation) may indicate a bleeding disorder and serve as a relative contraindication to full-dose anticoagulation.

Activated prothrombin time (APTT): A PTT test in which an activator substance is added which speeds up the clotting process, considered to be a more sensitive version of the PTT test.

Peer Reviewed Publications:

1. Bannoud MA, Martins TD, Montalvão SAL, et al. Integrating biomarkers for hemostatic disorders into computational models of blood clot formation: a systematic review. Math Biosci Eng. 2024; 21(12):7707-7739.
2. Benarroch-Gampel J, Sheffield KM, Duncan CB, et al. Preoperative laboratory testing in patients undergoing elective, low-risk ambulatory surgery. Ann Surg. 2012; 256(3):518-528.
3. Hemker HC. A century of heparin: past, present and future. J Thromb Haemost. 2016; 14(12):2329-2338.
4. Hemker HC, Al Dieri R, Béguin S. Heparins: a shift of paradigm. Front Med (Lausanne). 2019; 6:254.
5. Hogwood J, Mulloy B, Lever R, Gray E, Page CP. Pharmacology of heparin and related drugs: an update. Pharmacol Rev. 2023; 75(2):328-379.
6. Jacobs JW, Gisriel SD, Iyer K, Rinder HM. Concomitant factor VIII inhibitor and lupus anticoagulant in an asymptomatic patient. J Thromb Thrombolysis. 2022; 53(4):945-949.
7. Kruse-Jarres R. Acquired bleeding disorders in the elderly. Hematology Am Soc Hematol Educ Program. 2015; 2015:231-236.
8. Lee KC, Lee IO. Preoperative laboratory testing in elderly patients. Curr Opin Anaesthesiol. 2021; 34(4):409-414.
9. Levy JH, Connors JM. Heparin resistance - clinical perspectives and management strategies. N Engl J Med. 2021; 385(9):826-832.
10. Lurie JM, Png CYM, Subramaniam S, et al. Virchow's triad in "silent" deep vein thrombosis. J Vasc Surg Venous Lymphat Disord. 2019; 7(5):640-645.
11. Lv Y, Liu N, Li Y, et al. Coagulation dysfunction in patients with liver cirrhosis and splenomegaly and its countermeasures: a retrospective study of 1522 patients. Dis Markers. 2023; 2023:5560560.
12. Malpani R, Mclynn RP, Bovonratwet P, et al. Coagulopathies are a risk factor for adverse events following total hip and total knee arthroplasty. Orthopedics. 2020; 43(4):233-238.
13. Mari D, Ogliari G, Castaldi D, et al. Hemostasis and ageing. Immun Ageing. 2008; 5:12.
14. Taylor GA, Liu JC, Schmalbach CE, et al. Preoperative laboratory testing among low-risk patients prior to elective ambulatory endocrine surgeries: a review of the 2015-2018 NSQIP cohorts. Am J Surg. 2021; 222(3):554-561.
15. Thachil J. Clinical differentiation of anticoagulant and non-anticoagulant properties of heparin. J Thromb Haemost. 2020; 18(9):2424-2425.
16. Winter WE, Flax SD, Harris NS. Coagulation testing in the core laboratory. Lab Med. 2017; 48(4):295-313.
17. Yang T, Wei J, Wang Z, et al. Analysis of risk factors and prediction model construction of deep vein thrombosis in patients with lumbar degenerative diseases before surgery. Sci Rep. 2025; 15(1):26069.
18. Zaidi SRH, Rout P. Interpretation of blood clotting studies and values (PT, PTT, APTT, INR, Anti-Factor Xa, D-Dimer). 2024 Jun 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan -. PMID: 38861642.

Government Agency, Medical Society, and Other Authoritative Publications:

1. Apfelbaum JL, Connis RT, Nickinovich DG, et al.; American Society of Anesthesiologists (ASA) Task Force on Preanesthesia Evaluation on Standards and Practice Parameters. Practice advisory for preanesthesia evaluation: an updated report by the ASA Task Force on Preanesthesia Evaluation. Anesthesiology. 2012; 116(3):522-538.
2. Garcia DA, Baglin TP, Weitz JI, Samama MM. Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012 Feb;141(2 Suppl):e24S-e43S.
3. McMichael ABV, Ryerson LM, Ratano D, et al. 2021 ELSO adult and pediatric anticoagulation guidelines. ASAIO J. 2022; 68(3):303-310.
4. NCCN Clinical Practice Guidelines in Oncology^®. ^© 2025 National Comprehensive Cancer Network, Inc. For additional information visit the NCCN website: http://www.nccn.org/index.asp. Accessed on November 2, 2025.
   • Acute Myeloid Leukemia. V2.2026. Revised October 2, 2025.
   • Cancer-Associated Venous Thromboembolic Disease. V2.2025. Revised May 22, 2025.
5. Schilsky ML, Roberts EA, Bronstein JM, et al. A multidisciplinary approach to the diagnosis and management of Wilson disease: 2022 practice guidance on wilson disease from the American Association for the Study of Liver Diseases. Hepatology. 2025; 82(3):E41-E90.
6. Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al.; Treatment Guidelines Working Group on Behalf of The World Federation Of Hemophilia. Guidelines for the management of hemophilia. Haemophilia. 2013; 19(1):e1-47.
7. Tomaselli GF, Mahaffey KW, Cuker A, et al. 2020 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2020; 76(5):594-622.

1. National Blood Clot Alliance. Unfractionated Heparin. https://www.stoptheclot.org/about-clots/blood-clot-treatment/unfractionated-heparin/#:~:text=UFH%20is%20the%20preferred%20treatment,inaccurately%20as%20%E2%80%9
   Cheparin%20allergy%E2%80%9D. Accessed on October 21, 2025.

The use of specific product names is illustrative only. It is not intended to be a recommendation of one product over another, and is not intended to represent a complete listing of all products available.

Activated thromboplastin time
APTT
partial thromboplastin time
Heparin
PTT

Federal and State law, as well as contract language, and Medical Policy take precedence over Clinical UM Guidelines. We reserve the right to review and update Clinical UM Guidelines periodically. Clinical guidelines approved by the Medical Policy & Technology Assessment Committee are available for general adoption by plans or lines of business for consistent review of the medical necessity of services related to the clinical guideline when the plan performs utilization review for the subject. Due to variances in utilization patterns, each plan may choose whether to adopt a particular Clinical UM Guideline. To determine if review is required for this Clinical UM Guideline, please contact the customer service number on the member's card.

Alternatively, commercial or FEP plans or lines of business which determine there is not a need to adopt the guideline to review services generally across all providers delivering services to Plan’s or line of business’s members may instead use the clinical guideline for provider education and/or to review the medical necessity of services for any provider who has been notified that his/her/its claims will be reviewed for medical necessity due to billing practices or claims that are not consistent with other providers, in terms of frequency or in some other manner.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

© CPT Only - American Medical Association